In one of those situations when actual clinical practice precedes the normal drug development process a recent announcement from Janssen Research & Development, LLC (Johnson & Johnson) informs that they have un-blinded their Phase 3 study, COU-AA-302, which clearly demonstrates that Zytiga (abiraterone acetate), when taken with prednisone, is effective in treating both mildly symptomatic [...]
One of the common side effects reported from chemotherapy with Taxotere is neuropathy. In the trial used to receive FDA approval, TAX 327 which had 332 patients. In that trial the following percentage of men reported incidents of neuropathy: Neuropathy Sensory- Nerve damage causing tingling or pain, usually in feet or hands: Any Grade- 30.4% [...]
Denosumab (Xgeva), the recently approved and only therapy that prolongs bone metastasis-free survival in men with non-metastatic castrate-resistant prostate cancer (CRPC) who are at high risk for the spread of prostate cancer metastasis to bone seems to work best in men with very rapid prostate specific antigen (PSA) kinetics. The large 1,432 man, placebo controlled, [...]
Over the years there has been discussion about using Photo Dynamic Therapy to destroy internal tumors, including prostate cancer tumors. Until now it has only been a hope since there is no way to monitor the amount of light that is actually administered to an internal tumor. We currently use laser light in combination with [...]
Abstract No:101 at the recent ASCO Conference It is sad, but it is true, a subset of men presenting with advanced prostate cancer never receive proper therapy. This can be attributed to a variety of factors including poor functional status, co-morbidities, and patient preference. The researchers sought to determine the prevalence, and characteristics, of this [...]
At the 2012 Genitourinary Cancers Symposium ASCO conference, Dr. Philip Kantoff (Dana-Farber Cancer Institute, Harvard Medical School Boston, MA) suggested taking a personalized approach to the individualized treatment plan for all men suffering from advanced prostate cancer. Dr. Kantoff said, “Few patients with advanced prostate cancer are currently cured with ADT (but anecdotally, long-term survival [...]
Prior to the formal review, the FDA has raised questions about the ultimate approval of Amgen’s Xgeva (denosumab) for men with metastatic, advanced prostate cancer who have not yet developed metastasized to the bone. Xgeva has been shown to delay tumors spreading to bones, but it does not extend life, the holy grail of the [...]
As a follow up to my last post about the three posters that appeared at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium meeting I am going to share with you a video interview with Dr. Chadi Nabhan. Dr. Nabhan talks about his presentation about the phase III results of the Provenge IMPACT [...]
The American Society of Clinical Oncologists (ASCO) posted on Wednesday the abstracts from the Genitourinary Conference which is scheduled for February 2-4 in San Francisco, California. Dendreon, the creator of the immunotherapy Provenge for men with metastatic castrate resistant advanced prostate cancer has three very interesting and informative posters which will appear at the conference. [...]
Radium-223 choride, also known as Alpharadin, has demonstrated a small but statistically significant survival benefit in men with symptomatic metastatic castrate resistant prostate cancer (mCRPC). My expectation is that it will be approved by the FDA some time later this year. Additionally, my hope is that it will also be approved Europe. To read more [...]
